Bicara Therapeutics BCAX 深 沪
已收盘 10-02 16:00:00 美东时间
17.63
-0.570
-3.13%
华盛通- 最 高18.9575
- 今 开18.50
- 成交量 76.31万股
- 最 低 17.56
- 昨 收 18.20
- 总市值 11.67亿
- 52周最高 30.99
- 市盈率 静 --
- 换手率 1.15%
- 52周最低 13.70
- 委 比 -73.81%
- 总股本 6617.29万
- 历史最高 30.99
- 量 比 1.05
- 振 幅 7.68%
- 历史最低 7.80
- 每 手 1
- 风险率 3.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Pliant Therapeutics appoints David Raben, M.D., as Chief Medical Officer. With over 30 years of oncology expertise, Raben brings significant experience in drug development and clinical trials. His leadership is expected to advance the company's PLN-101095 program, a targeted therapy for solid tumors. Raben previously led clinical development at Bicara Therapeutics and held key roles at Amgen and Genentech, focusing on innovative cancer treatments...
09-30 20:10
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology announced positive updated data from its Phase 1 study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The updated results showed a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR). Median progression-free survival (mPFS) was 6.2 months, and the 12-month overall survival (OS) probability was 79%. No new sa...
09-09 11:00
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35
BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.
08-19 17:56
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday. The company posted quarterly losses of 82 cents per share which beat the analyst consensus estimate of losses of 84 cents per share. This represents a 64% decrease over losses of 50 cents ...
08-12 20:34
Bicara Therapeutics shares are trading lower after the company reported a wider net loss for the second quarter reflecting rising expenses.
Bicara Therapeutics shares are trading lower after the company reported a wider net loss for the second quarter reflecting rising expenses.
08-12 01:06
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of $(0.50) per share from the same period last year.
08-11 19:30
Bicara Therapeutics reshapes board for commercialization push
Bicara Therapeutics Inc. ( ($BCAX) ) just unveiled an update. On July 28, 2026,...
07-28 20:59
